To further confirm the role of CDRs in prostate cancer cell growth, we ablated the endogenous expression of CDC20, RRM2, and DTL with cutting-edge RNA-targeted CRISPR-Cas13 (Fig. 4I, J). The gene discussed is CDC20; the disease is prostate cancer.